Corporate Misconduct Accountability Project
Johnson & Johnson Services, Inc. · Class Action
Johnson & Johnson Accused of Hiding Tylenol PM Addiction Risk
Class action alleges pharmaceutical giant falsely marketed diphenhydramine sleep aids as non habit-forming despite scientific evidence of tolerance and dependence, deceiving millions of consumers seeking safe insomnia relief.
HIGH SEVERITY
TL;DR
Johnson & Johnson Services, Inc. faces a class action lawsuit alleging it falsely labeled Tylenol PM products as non habit-forming when the active ingredient diphenhydramine is scientifically known to cause tolerance and dependence. Plaintiff Sirreon Goodson purchased the product in California, relying on the non habit-forming claim, only to develop a nightly habit. The lawsuit claims millions of consumers paid premium prices for products marketed as safe alternatives to prescription sleep aids, when in reality the products posed risks of psychological and physical dependence, adverse health effects including dementia risk in elderly users, and next-day impairment.
If you purchased Tylenol PM or similar diphenhydramine products marketed as non habit-forming, you may have been misled about serious health risks.
$65B
Annual global over-the-counter sleep aid market revenue
22%
U.S. adults regularly using OTC sleep aids (2023 survey)
1-2 weeks
Time for diphenhydramine tolerance to develop
13,574
Antihistamine-positive overdose deaths (2019-2020)
71.1%
Of those deaths involving diphenhydramine specifically
The Allegations: A Breakdown
Core Allegations
What Johnson & Johnson is accused of doing · 8 points
| 01 | Johnson & Johnson Services prominently labeled Tylenol PM Extra Strength products as non habit-forming on the front packaging, despite diphenhydramine HCl being scientifically known to cause tolerance in as little as 1-2 weeks and lead to psychological and physical dependence. | high |
| 02 | The company allegedly knew or should have known the non habit-forming claim was false based on substantial research showing diphenhydramine elicits a cocaine-like pattern of dopamine transmission that can lead to medication misuse. | high |
| 03 | Johnson & Johnson deliberately placed the non habit-forming claim on the primary display panel next to product descriptions to grab consumer attention and induce reliance, according to the complaint. | high |
| 04 | The company allegedly conducted internal market research showing the non habit-forming claim would lead consumers to believe the product was safe and would not result in habitual use, yet continued using the claim to drive sales. | high |
| 05 | Consumers paid a price premium for products they believed were safer alternatives to prescription sleep aids, when in reality the products posed serious risks including tolerance requiring higher doses, dependence, and potential overdose. | high |
| 06 | The lawsuit alleges Johnson & Johnson had exclusive control over the labeling and could have easily stopped using the misleading claim but deliberately chose to continue it to maximize profits. | medium |
| 07 | Plaintiff Goodson purchased Tylenol PM from Walmart and Walgreens in Sacramento in November 2023, saw the non habit-forming label, trusted it, and subsequently developed a habit contrary to the product claims. | high |
| 08 | The company allegedly violated California consumer protection laws including the Consumer Legal Remedies Act, Unfair Competition Law, and False Advertising Law, as well as common law claims for breach of warranty, fraud, and unjust enrichment. | medium |
Public Health and Safety
Documented health risks hidden from consumers · 8 points
| 01 | Diphenhydramine easily penetrates the blood-brain barrier and interferes with H1 receptors, causing drowsiness. Users quickly develop tolerance requiring larger and larger doses for the same effect, leading to dependence where users need the drug to fall asleep. | high |
| 02 | According to CDC data from 2019-2020, among 92,033 overdose deaths, 13,574 were antihistamine-positive and 3,345 were antihistamine-involved. Nearly all involved first-generation antihistamines, primarily diphenhydramine which accounted for 71.1% of antihistamine-positive deaths. | critical |
| 03 | Diphenhydramine was among the ten drugs most frequently involved in overdose deaths in 2017, alongside fentanyl, heroin, cocaine, methamphetamine, and other controlled substances. | critical |
| 04 | In adults 65 years and older, long-term frequent use of first-generation antihistamines like diphenhydramine is associated with development of dementia and Alzheimer’s disease due to anticholinergic properties. | high |
| 05 | Hospitalized elderly people treated with diphenhydramine have increased risk of delirium. Overdose can lead to sedation progressing to coma, with elderly adults more sensitive to this toxicity. | high |
| 06 | The half-life of diphenhydramine can be as long as 18 hours, causing next day hangover effects including poor attention, reduced memory, poor sensory-motor performance, and impaired driving worse than alcohol. | high |
| 07 | Cardiac toxicity from prolonged QTc and arrhythmias has been reported with diphenhydramine use. | medium |
| 08 | The Canadian Society of Allergy and Clinical Immunology recommends first-generation antihistamines like diphenhydramine should only be available behind-the-counter. The Global Allergy and Asthma European Network supports prescription requirements for these drugs. | medium |
Profit Over People
How financial incentives drove misleading marketing · 6 points
| 01 | The global over-the-counter sleep aid market generates nearly $65 billion annually, a number that continues to rise. Johnson & Johnson capitalized on this massive market by repackaging allergy medication as sleep aids. | high |
| 02 | A 2023 survey found 22% of U.S. adults reported using over-the-counter sleep aids, representing millions of consumers and a captive market for pharmaceutical companies. | medium |
| 03 | Johnson & Johnson took diphenhydramine, first marketed as Benadryl for allergies in 1946 before modern safety testing requirements, and repackaged it for sleep after recognizing its sedating side effects could be exploited for profit. | high |
| 04 | The complaint alleges manufacturers reserve the front primary display panel of packaging for the most important and persuasive information they believe will motivate purchases. The conspicuous placement of non habit-forming demonstrates the company’s awareness this claim drives sales. | high |
| 05 | Despite knowledge that the non habit-forming claim was false and that consumers rely on it when purchasing, Johnson & Johnson deliberately chose to continue the misleading marketing to avoid losing sales revenue. | high |
| 06 | The company’s constant unqualified use of the non habit-forming claim evidences its intent to convince consumers the product conforms to the claim and ultimately drive sales, according to the lawsuit. | medium |
Corporate Accountability Failures
Scientific evidence the company allegedly ignored · 8 points
| 01 | A substantial body of research demonstrates diphenhydramine is habit-forming or more likely than not to be habit-forming, yet Johnson & Johnson continued marketing products as non habit-forming for at least four years with no material changes to packaging. | high |
| 02 | Multiple peer-reviewed studies document diphenhydramine addiction and misuse, including research published in Frontiers in Psychiatry, Neurology Clinical Practice, Psychiatry Praxis, Journal of Psychopharmacology, and JAMA spanning from 1986 to 2021. | high |
| 03 | Published research shows tolerance to daytime sedative effects of H1 antihistamines can develop quickly, requiring users to take larger doses. One study found tolerance developed in as little as 1-2 weeks. | high |
| 04 | Studies document diphenhydramine dependence cases in adolescents, children with chronic illnesses, and adults requiring detoxification programs. Medical rehabilitation communities have created programs specifically to combat diphenhydramine dependency. | high |
| 05 | Research shows diphenhydramine elicits a cocaine-like pattern of dopamine transmission that can lead to misuse. Continuous use may cause the medication to stop working as well, perpetuating higher dose escalation. | high |
| 06 | The abuse of Benadryl (containing the same active ingredient as Tylenol PM) is well-documented by medical and rehabilitation communities. A Google search of diphenhydramine addiction yields hundreds of results pointing to detox programs. | medium |
| 07 | Despite this extensive body of evidence available to the company, Johnson & Johnson named and marketed the product with the non habit-forming claim but formulated it with diphenhydramine in a manner that does not conform to the representation. | high |
| 08 | The complaint alleges the company had reason to know the non habit-forming representation was false when it made the claim and deliberately misrepresented the product to induce consumer purchases. | high |
Economic Fallout
Financial harm to consumers and communities · 6 points
| 01 | Consumers paid a price premium for Tylenol PM products because they were sold at higher prices due to the non habit-forming misrepresentations, or they would not have purchased the products at all had they known the truth. | high |
| 02 | Consumers incurred additional healthcare expenses including doctor visits, potential detox programs, and extended counseling for those who developed psychological dependence on products marketed as safe. | high |
| 03 | The next-day hangover effects from diphenhydramine use caused workplace absenteeism and decreased productivity, burdening the labor force and causing lost wages for workers. | medium |
| 04 | Families experienced financial hardship when household members struggled with mental and physical consequences of long-term diphenhydramine use, creating tension and unexpected medical costs. | medium |
| 05 | Overuse and side effects requiring medical intervention indirectly inflated insurance premiums for entire communities while Johnson & Johnson reaped billions in revenue. | medium |
| 06 | Lower-income consumers lacking robust health insurance to afford prescription treatments or therapy were more likely to purchase the supposedly cheap fix, ironically creating an ongoing cost burden and health hazard. | high |
Community Impact
How vulnerable populations bore the greatest harm · 6 points
| 01 | Local community health clinics saw upticks in patients complaining of chronic sleeplessness despite using Tylenol PM, or older adults experiencing confusion, memory lapses, and early dementia signs correlated to frequent antihistamine use. | high |
| 02 | The underinsured and unemployed who could barely afford consistent healthcare fell deeper into health crises after relying on products falsely marketed as safe non habit-forming solutions. | high |
| 03 | Small businesses saw productivity declines when employees arrived groggy or disoriented due to next-day sedation from diphenhydramine products they believed were safe for nightly use. | medium |
| 04 | Families experienced tension when spouses or parents grew mentally dependent on nightly pills to cope, trusting the non habit-forming label that disarmed their concerns about daily use. | medium |
| 05 | People living in lower socioeconomic brackets face heightened stress and longer working hours, making them more prone to pick up over-the-counter solutions. The cheap fix became an added burden for those barely scraping by. | high |
| 06 | Overworked single mothers, overwhelmed college students, and elderly consumers particularly vulnerable to confusion and sedation trusted the non habit-forming label and suffered consequences ranging from doubled doses to increased dementia risk. | high |
Regulatory Failures
Gaps in oversight that enabled the misconduct · 5 points
| 01 | Diphenhydramine burst onto the market in 1946 as Benadryl when medications were not required to pass rigorous drug safety or efficacy testing, allowing it to be grandfathered in without modern scrutiny. | high |
| 02 | Despite decades of accumulating evidence about diphenhydramine tolerance and dependence, the FDA has not required manufacturers to remove non habit-forming claims from product labels. | high |
| 03 | There are no asterisks or qualifying disclosures on the non habit-forming claim, and even if buried warnings exist in fine print, reasonable consumers are unlikely to see them at time of purchase. | medium |
| 04 | The complaint notes that if studies show habit formation is possible, it is time for the FDA to clamp down on misleading phrases, but to date no such action has been taken. | medium |
| 05 | International medical organizations including the Canadian Society of Allergy and Clinical Immunology and Global Allergy and Asthma European Network recommend behind-the-counter or prescription-only status for first-generation antihistamines, yet U.S. regulators have not followed suit. | medium |
The PR Machine
How corporate messaging obscured the truth · 6 points
| 01 | Johnson & Johnson leverages its storied history and brand recognition built on trust to market Tylenol PM, with consumers from new mothers to headache sufferers seeing the brand presence as comforting and reliable. | medium |
| 02 | The company points to philanthropic donations, patient assistance programs, and corporate social responsibility initiatives to highlight supposed commitment to consumer well-being while allegedly misleading consumers about product safety. | high |
| 03 | Johnson & Johnson’s carefully designed labels and packaging, including strategic placement of the non habit-forming claim, perpetuate the false notion that the product is safe for regular use without consequences. | high |
| 04 | The lawsuit alleges the defendant intended that consumers viewing the product labels would read the claim, understand it as a warranty of safety, and rely on it when making purchase decisions. | medium |
| 05 | Manufacturers repeat marketing claims to emphasize and characterize a brand, shaping consumer expectations because they believe repeated messages drive purchases. The constant use of non habit-forming evidences intent to convince consumers and drive sales. | medium |
| 06 | The phrase non habit-forming is psychologically powerful, disarming users by suggesting nightly use is safe. Reasonable consumers assume packaging statements are true and have no reason to independently verify them. | high |
The Bottom Line
What this case reveals about corporate power · 8 points
| 01 | This lawsuit represents countless Americans who trusted a major pharmaceutical brand’s promise of safe, non habit-forming sleep aid only to discover they developed dependencies the company said would not occur. | high |
| 02 | The case exemplifies how under neoliberal capitalism, corporations factor consumer harm into cost-benefit calculations, continuing profitable but potentially dangerous practices until lawsuits or scandals force change. | high |
| 03 | Plaintiff Goodson seeks not just personal damages but injunctive relief to force Johnson & Johnson to remove or correct the misleading label, potentially benefiting millions of consumers nationwide. | medium |
| 04 | The complaint alleges violations of multiple California consumer protection statutes and common law, seeking compensatory damages, restitution, injunctive relief, and attorney fees on behalf of nationwide and California classes. | medium |
| 05 | A CLRA demand letter was sent to Johnson & Johnson on October 23, 2024 providing notice of violations and demanding corrective action, but the company apparently declined to remedy the situation before the lawsuit was filed. | medium |
| 06 | The case demonstrates that corporate social responsibility programs and philanthropic contributions do not offset systematic marketing of potentially habit-forming products to unsuspecting consumers or excuse misleading labeling. | high |
| 07 | Unless penalties for misrepresenting product hazards outweigh profits gained from misleading claims, deep-pocketed corporations have little financial incentive to prioritize consumer safety over shareholder returns. | high |
| 08 | The lawsuit argues that people seeking better sleep should not have to sacrifice their health or face hidden dependency traps, and no brand should be allowed to undermine public well-being under the guise of non habit-forming claims. | high |
Timeline of Events
1946
Benadryl containing diphenhydramine first enters U.S. market before modern drug safety testing requirements. Users quickly identify sedating effects.
1980s-2020s
Multiple peer-reviewed studies published documenting diphenhydramine addiction, dependence, and misuse cases across diverse patient populations.
2017
CDC data identifies diphenhydramine among the ten drugs most frequently involved in overdose deaths in the United States.
2019-2020
Among 92,033 overdose deaths, 13,574 were antihistamine-positive with diphenhydramine accounting for 71.1% of those deaths.
2020-2024
Johnson & Johnson continues marketing Tylenol PM with prominent non habit-forming label despite growing body of scientific evidence to the contrary.
November 2023
Plaintiff Sirreon Goodson purchases Tylenol PM from Walmart and Walgreens in Sacramento, California, relying on non habit-forming claim and subsequently develops habit.
October 2024
CLRA demand letter sent to Johnson & Johnson headquarters and registered agent via certified mail demanding corrective action for misleading labeling.
November 13, 2024
Class action complaint filed in U.S. District Court for the Eastern District of California alleging consumer protection violations and seeking injunctive relief.
Direct Quotes from the Legal Record
QUOTE 1
The false promise on every package
allegations
“The Products containing Diphenhydramine HCL and prominently stating on the front of their label that they are ‘Non-habit forming.'”
💡 This prominent front-label claim is the core misrepresentation that allegedly deceived millions of consumers into believing the product was safe for regular use.
QUOTE 2
Rapid development of tolerance
health
“Because the chemical floods the brain in large quantities, users can quickly develop a tolerance. Tolerance can develop in as little as 1–2 weeks, requiring users to take larger and larger doses for the same sedating effect, and causing dependency in users who find they need diphenhydramine to fall asleep.”
💡 Scientific evidence directly contradicts Johnson & Johnson’s non habit-forming claim, showing the product causes dependence in a matter of weeks.
QUOTE 3
Among the deadliest drugs
health
“Among drug overdose deaths in 2017 that mentioned at least one specific drug on the death certificate, the ten drugs most frequently involved included fentanyl, heroin, cocaine, methamphetamine, alprazolam, oxycodone, morphine, methadone, hydrocodone, and diphenhydramine.”
💡 Diphenhydramine ranks alongside highly controlled and deadly substances in overdose deaths, yet Johnson & Johnson markets it as safe and non habit-forming over-the-counter.
QUOTE 4
Staggering overdose toll
health
“According to the CDC, among 92,033 overdose deaths during 2019–2020, 13,574 (14.7%) were antihistamine-positive and 3,345 (3.6%) were antihistamine-involved. Nearly all antihistamine-positive and -involved deaths (13,475, 99.6%; 3,339, 99.8%, respectively) included first-generation H1 antihistamines, primarily diphenhydramine (9,645, 71.1%; 2,226, 66.5%, respectively).”
💡 CDC data proves diphenhydramine is involved in thousands of deaths annually, undermining any claim the product is safe for unrestricted consumer use.
QUOTE 5
Dementia risk in elderly users
health
“In adults 65 years and older, long-term, frequent use of first-generation antihistamines like diphenhydramine is associated with development of dementia and Alzheimer disease due to their anticholinergic properties.”
💡 Johnson & Johnson’s marketing encourages regular use in exactly the population most vulnerable to devastating long-term cognitive harm.
QUOTE 6
More dangerous than alcohol
health
“These hang-over effects can be dangerous. For example, in a simulation of 40 drivers, diphenhydramine resulted in the poorest driving performance – lower than that that of alcohol.”
💡 Research shows diphenhydramine impairs driving worse than alcohol, yet the product is marketed for nightly use with no warnings about next-day impairment.
QUOTE 7
International calls for restrictions
regulatory
“Because of this evidence, Canadian Society of Allergy and Clinical Immunology recommends that first-generation antihistamines such as diphenhydramine should be considered for availability only on a behind-the-counter basis. The Global Allergy and Asthma European Network also supports implementing a prescription requirement for first-generation antihistamines like diphenhydramine.”
💡 International medical authorities recognize diphenhydramine is too dangerous for unrestricted access, yet U.S. regulators allow non habit-forming marketing.
QUOTE 8
Cocaine-like addiction pattern
accountability
“Diphenhydramine elicits a cocaine-like pattern of stimulation of dopamine transmission that can lead to misuse of medications containing diphenhydramine.”
💡 Scientific research shows the drug triggers brain addiction pathways similar to cocaine, directly contradicting non habit-forming claims.
QUOTE 9
Plaintiff developed the promised habit
allegations
“When Mr. Goodson purchased Johnson & Johnson Services, Inc.’s Tylenol PM, he saw it described as ‘non-habit forming’ on the label and trusted those statements. It mattered to him – as it does to millions of consumers – that he could find the advertised benefits, relief, and support of a pain reliever and nighttime sleep-aid without developing a habit. But he did develop a habit.”
💡 The plaintiff’s experience proves the non habit-forming claim is false in real-world use, forming the basis for class-wide relief.
QUOTE 10
Company knew the claim was false
accountability
“Defendant knew, or should have known, that the ‘non habit-forming’ claim was false, misleading, deceptive, and unlawful, at the time that Defendant manufactured, marketed, advertised, labeled, and sold the Product using the ‘non habit-forming’ claim to Plaintiff and the Class.”
💡 The lawsuit alleges Johnson & Johnson had knowledge of the falsity, elevating this from negligence to potential fraud.
QUOTE 11
Targeting vulnerable consumers
profit
“Consumers desire products that are safe and do not contain significant side effects. They also prefer and desire sleep-aid products that do not cause habitual use. Johnson & Johnson Services, Inc. has capitalized on those consumer preferences by falsely promising that its Tylenol PM products are ‘non habit-forming.'”
💡 The company deliberately exploited consumer desire for safe products by making promises it knew were false.
QUOTE 12
Massive market profiteering
profit
“Today, the over-the-counter sleep-aid market is a global juggernaut, reaping nearly $65 billion a year – a number which is only continuing to rise.”
💡 Johnson & Johnson profits from a massive market built on potentially false safety claims worth tens of billions annually.
QUOTE 13
No adequate remedy at law
conclusion
“Injunctive relief is necessary to prevent Defendant from continuing to engage in the unfair, fraudulent, and/or unlawful conduct described herein and to prevent future harm – none of which can be achieved through available legal remedies (such as monetary damages to compensate past harm).”
💡 The lawsuit seeks to stop ongoing consumer harm that monetary damages cannot address, requiring court orders to change corporate behavior.
Frequently Asked Questions
What is the main allegation against Johnson & Johnson in this lawsuit?
The lawsuit alleges Johnson & Johnson falsely labeled Tylenol PM products as non habit-forming when the active ingredient diphenhydramine is scientifically known to cause tolerance in 1-2 weeks and lead to psychological and physical dependence, deceiving consumers who relied on the safety claim.
What is diphenhydramine and why is it dangerous?
Diphenhydramine is a first-generation antihistamine that easily crosses the blood-brain barrier. It can cause rapid tolerance requiring higher doses, psychological and physical dependence, next-day impairment worse than alcohol, increased dementia risk in elderly users, and has been involved in over 9,600 overdose deaths in just two years according to CDC data.
How quickly can someone become dependent on diphenhydramine?
Scientific research cited in the complaint shows tolerance to diphenhydramine can develop in as little as 1-2 weeks of regular use, requiring users to take increasingly larger doses to achieve the same sedating effect and creating psychological dependence where users believe they cannot sleep without it.
Who is most at risk from these misleadingly labeled products?
Elderly consumers face heightened risks including delirium, confusion, and dementia. Lower-income individuals who cannot afford prescription treatments or therapy rely on these supposedly cheap fixes. Overworked parents, stressed college students, and anyone suffering from insomnia who trusts the non habit-forming label are vulnerable to developing dependencies.
What does the CDC data show about diphenhydramine overdoses?
CDC data from 2019-2020 shows that among 92,033 overdose deaths, diphenhydramine was present in 9,645 cases (71.1% of all antihistamine-positive deaths). Diphenhydramine ranked among the ten drugs most frequently involved in fatal overdoses alongside fentanyl, heroin, and cocaine.
Did Johnson & Johnson know about the risks?
The lawsuit alleges the company knew or should have known the non habit-forming claim was false based on substantial published research spanning decades, internal marketing studies showing consumer reliance on the claim, and the well-documented addiction patterns associated with diphenhydramine including rehabilitation programs specifically for diphenhydramine dependency.
What relief is the plaintiff seeking?
Plaintiff Sirreon Goodson seeks class certification for nationwide and California consumers, compensatory and punitive damages, restitution, injunctive relief requiring Johnson & Johnson to remove or correct the misleading non habit-forming label, and attorney fees. The goal is both compensation for past harm and prevention of future consumer deception.
How much money is at stake in the sleep aid market?
The global over-the-counter sleep aid market generates nearly $65 billion annually and continues growing. A 2023 survey found 22% of U.S. adults regularly use OTC sleep aids, representing millions of consumers and massive revenue streams for pharmaceutical companies like Johnson & Johnson.
What should I do if I have purchased Tylenol PM products?
If you purchased Tylenol PM or similar diphenhydramine-based products marketed as non habit-forming and experienced tolerance, dependence, or adverse effects, you may be part of the proposed class. Consider consulting with a consumer protection attorney to understand your rights. The lawsuit was filed November 13, 2024 in the U.S. District Court for the Eastern District of California.
Why do international medical organizations want restrictions on these drugs?
The Canadian Society of Allergy and Clinical Immunology recommends diphenhydramine be available only behind-the-counter, and the Global Allergy and Asthma European Network supports prescription requirements for first-generation antihistamines. These recommendations reflect growing evidence of serious health risks including tolerance, dependence, overdose potential, and long-term cognitive harm.
💡 Explore Corporate Misconduct by Category
Corporations harm people every day — from wage theft to pollution. Learn more by exploring key areas of injustice.
- 💀 Product Safety Violations — When companies risk lives for profit.
- 🌿 Environmental Violations — Pollution, ecological collapse, and unchecked greed.
- 💼 Labor Exploitation — Wage theft, worker abuse, and unsafe conditions.
- 🛡️ Data Breaches & Privacy Abuses — Misuse and mishandling of personal information.
- 💵 Financial Fraud & Corruption — Lies, scams, and executive impunity.
